Verastem (VSTM) Stock Price, News & Analysis

Company Overview

Verastem Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S. Food and Drug Administration approval in 2018 for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. In parallel, Verastem Oncology has built a differentiated pipeline of targeted therapies, including selective Rho/MRTF pathway inhibitors and focal adhesion kinase (FAK) inhibitors, which are being evaluated in various solid tumor and blood cancer settings. Ongoing clinical trials are designed to explore monotherapy activity as well as combination regimens that may overcome resistance and improve patient outcomes.

Verastem Oncology conducts its clinical and translational research activities primarily in the United States, with strategic partnerships and investigator-initiated studies extending into Europe. The company collaborates with academic institutions and industry partners to accelerate the development of its pipeline assets. Verastem Oncology’s leadership team comprises experienced drug developers and oncology specialists who are committed to advancing novel therapies that address unmet medical needs in cancer treatment.

Key Stats

• Today's Range: $8.75 to $9.15
• 50-Day Range: $4.89 to $10.77
• 52-Week Range: $2.54 to $11.24
• Volume: 1.46 million shs
• Average Volume: 1.87 million shs
• Market Capitalization: $557.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.29
• Consensus Rating: Buy

Verastem Stock Analysis - MarketRank™

Verastem scored higher than 55% of companies evaluated by MarketBeat, and ranked 456th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Verastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Verastem has a consensus price target of $13.29, representing about 48.3% upside from its current price of $8.96.

Amount of Analyst Coverage

Verastem has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Verastem are expected to grow in the coming year, from ($3.02) to ($2.93) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Verastem is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Verastem is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

28.22% of the float of Verastem has been sold short.

Short Interest Ratio / Days to Cover

Verastem has a short interest ratio ("days to cover") of 6.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Verastem does not currently pay a dividend.

Dividend Growth

Verastem does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

28.22% of the float of Verastem has been sold short.

Short Interest Ratio / Days to Cover

Verastem has a short interest ratio ("days to cover") of 6.

Change versus previous month

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.01

News Sentiment

Verastem has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Verastem this week, compared to 5 articles on an average week.

Search Interest

25 people have searched for VSTM on MarketBeat in the last 30 days. This is an increase of 4% compared to the previous 30 days.

MarketBeat Follows

3 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,424.00 in company stock.

Percentage Held by Insiders

Only 2.10% of the stock of Verastem is held by insiders.

Percentage Held by Institutions

88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VSTM Stock Analysis - Frequently Asked Questions

How have VSTM shares performed this year?

Verastem's stock was trading at $5.17 at the beginning of the year. Since then, VSTM stock has increased by 73.3% and is now trading at $8.96.

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) released its quarterly earnings data on Thursday, August, 7th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.25. The biopharmaceutical company earned $2.14 million during the quarter, compared to analysts' expectations of $6.01 million.
Read the conference call transcript.

When did Verastem's stock split?

Shares of Verastem reverse split on the morning of Thursday, June 1st 2023.The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Who are Verastem's major shareholders?

Verastem's top institutional shareholders include Balyasny Asset Management L.P. (6.83%), BVF Inc. IL (5.53%), Nantahala Capital Management LLC (4.80%) and Armistice Capital LLC (3.47%). Insiders that own company stock include Dan Paterson, Daniel Calkins, Brian M Stuglik and Robert E Gagnon.
View institutional ownership trends.

How do I buy shares of Verastem?

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Verastem investors own include TherapeuticsMD (TXMD), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU) and Gilead Sciences (GILD).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/22/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VSTM
• CIK: 1526119
• Web: www.verastem.com
• Phone: (781) 292-4200
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Verastem: $13.29
• High Price Target: $20.00
• Low Price Target: $8.00
• Potential Upside/Downside: +46.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$130.64 million
• Net Margins: N/A
• Pretax Margin: -7,785.21%
• Return on Equity: -2,003.62%
• Return on Assets: -119.85%

Debt

• Debt-to-Equity Ratio: 2.06
• Current Ratio: 3.46
• Quick Ratio: 3.44

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 55,693.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.65) per share
• Price / Book: -13.92

Miscellaneous

• Outstanding Shares: 61,540,000
• Free Float: 60,253,000
• Market Cap: $556.94 million
• Optionable: Optionable
• Beta: 0.92